Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPROOT study of obinutuzumab in primary Sjögren's syndrome
NL-OMON59705Phase 2Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in primary Sjögren's syndrome, sponsored by Radboud University Medical Center. Primary endpoint: Depletion of autoreactive B cells in blood and tissues. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
obinutuzumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON59705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59705.